Thrombosis of great vein of Galen caused by Factor XIII concentrate: A case report-Reference-Cited by-同舟云学术

Thrombosis of great vein of Galen caused by Factor XIII concentrate: A case report

Published:2020 Issue:3 Volume:42 Page:196-202
ISSN:0912-0726
Container-title:Japanese Journal of Stroke
language:en
Short-container-title:Jpn. J. Stroke

Author:

Nakano Mizuki¹,Araki Yoshio¹,Kanamori Fumiaki¹,Uda Kenji¹,Yokoyama Kinya¹,Nishihori Masahiro¹,Izumi Takashi¹,Yoshimoto Masayuki²

Affiliation:

1. Department of Neurosurgery, Nagoya University Graduate School of Medicine

2. Department of Neurosurgery, Nakatsugawa Municipal General Hospital

Publisher

Japan Stroke Society

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jstroke/42/3/42_10720/_pdf

Reference18 articles.

1. 1) Tahlan A, Ahluwalia J: Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit. Arch Pathol Lab Med 138: 278–281, 2014

2. 2) Brackmann HH, Egbring R: Comparison of main pharmacokinetic variables of plasma-derived factor XIII concentrate (BI 71.023) and Fibrogammin®P (placenta-derived factor XIII/BI 2.021) 新薬と臨 42: 1377–1397, 1993

3. 4) Nakayama H, Ishikawa T, Yamashita S, et al: [CSF leakage and anosmia in aneurysm clipping of anterior communicating artery by basal interhemispheric approach]. No Shinkei Geka 39: 263–268, 2011 (in Japanese)

4. 5) Stam J: Thrombosis of the cerebral veins and sinuses. N Engl J Med 352: 1791–1798, 2005

5. 6) Ferro JM, Canhão P, Stam J, et al: Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35: 664–670, 2004

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful treatment of intractable pseudomeningocele with FXIII deficiency by surgery and FXIII replacement therapy: A case report;International Journal of Surgery Case Reports;2022-03

2. A Case of Traumatic Cerebrospinal Fluid Rhinorrhea Successfully Treated Using Intravenous Factor XIII Administration;Cureus;2021-06-14